Stem Cell and Derivatives

<p>VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.</p>

<p>RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Simian OC/BGP. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Simian OC/BGP. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Simian OC/BGP, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Simian OC/BGP in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse sCD14. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse sCD14. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse sCD14, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse sCD14 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human ASPP1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human ASPP1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human ASPP1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human ASPP1 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Dog sCD14. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Dog sCD14. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Dog sCD14, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Dog sCD14 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse CC17. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse CC17. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse CC17, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse CC17 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat sCD14. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat sCD14. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat sCD14, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat sCD14 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse sCD14. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse sCD14. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse sCD14, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse sCD14 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse TNC. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse TNC. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse TNC, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse TNC in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat Cys-C. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat Cys-C. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat Cys-C, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse CC17. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse CC17. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse CC17, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse CC17 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.

<p>Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).</p>

<p>Dilpacimab (ABT165) is a dual-variable antibody that targets DLL4 and VEGF pathways, showing potential in cancer research by blocking angiogenesis and Notch.</p>

<p>Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32</p>

<p>"Tarlatamab (AMG-757), a BiTE antibody, targets DLL3, prevalent in SCLC tumors with scant normal tissue expression, and shows promise for SCLC research."</p>

<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>

<p>Trevogrumab is a human monoclonal antibody that inhibits myostatin (GDF8) to promote muscle growth, and is under research for treating age-related muscle loss (sarcopenia).</p>

<p>Nisevokitug (anti-TGF-β mAb) neutralizes TGF-β and is being studied for its ability to modulate the immunosuppressive tumor microenvironment.</p>

<p>Tarextumab is an anti-Notch2/3 mAb, a promising candidate for breast, lung, ovarian, and pancreatic cancers.</p>

<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>

<p>1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, &gt;100-fold selectivity over CDK1/cyclin B and CDK5/p25.</p>

<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>

<p>gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.</p>

<p>β-catenin/CBP-IN-1 is a potent and selective inhibitor of CBP/β-catenin</p>

<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>

<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>

<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>

<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>

<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>

<p>3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in</p>

<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>

<p>SIS3 free base is a potent and selective Smad3 phosphorylation inhibitor. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.</p>

<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>

<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>

<p>CJJ300 is a TGF-β inhibitor disrupting TGF-β-TβR complex formation, with an IC50 of 5.3 μM, and halts cell migration.</p>

<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>

<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>

<p>CK2α-IN-1 is a selective non-ATP-competitive CK2α inhibitor with an IC50 of 7.0 µM and a Ki of 1.6 µM.CK2α-IN-1 exhibits potential anticancer activity and can</p>

<p>CK2-IN-4 is a protein kinase (CK2) inhibitor with an IC50 value of 8.6 µM.</p>

<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>

<p>inS3-54-A26 is an inhibitor of the DNA-binding domain of STAT3. inS3-54-A26 suppresses tumor growth, metastasis and the gene expression of STAT3.</p>

<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>

<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>

<p>H-1152 is a potent, specific, ATP-competitive, and cell permeable ROCK inhibitor (Ki = 1.6 nM).</p>

<p>TEAD-IN-2 is a potent and bifunctional TEAD inhibitor to induce TEAD protein degradation via the ubiquitination pathway, with anticancer potential.</p>

<p>CAY10746 selectively inhibits ROCK I/II with IC50s: 0.014/0.003 μM, useful for diabetic retinopathy research.</p>

<p>ELN 318463 selectively inhibits γ-secretase; EC50: 12 nM (PS1), 656 nM (PS2); 51x more selective for PS1; targets APP.</p>

<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>

<p>GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β</p>

<p>SR-1277 is a potent, highly selective and ATP-competitive CK1δ/ε inhibitor, regulating Wee1 activity at the G2/M cell-cycle interface, and antiproliferative.</p>

<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>

<p>LY-411575 isomer 1 is a potent γ-secretase inhibitor. LY-411575 isomer 1 is an isomer of LY411575.</p>

<p>AF-2112, a TEAD inhibitor derived from Flufenamic acid, significantly diminishes the expression of CTGF, Cyr61, Axl, and NF2.</p>

<p>TEAD-IN-6 (Example 11-1) is a TEAD modulator that inhibits the YAP1/TAZ-TEAD interaction, and has applications in cancer research [1].</p>

<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>

<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>

<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>

<p>PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits</p>

<p>Aβ42-IN-2 is a γ-secretase modulator. Aβ42-IN-2 has an IC 50 of 6.5 nM for Αβ 42. Aβ42-IN-2 can be used for the Alzheimer's disease research[1].</p>

<p>Gamma-secretase modulator 2 selectively targets Alzheimer's by reducing Aβ(1-42), aiding in prevention and treatment.</p>

<p>tCFA15: A trimethylated long-chain fatty alcohol with a 15-carbon side chain; may regulate Notch signaling and neuron differentiation.</p>

<p>Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP).</p>

<p>γ-Secretase modulator 4 is a potent γ-secretase modulator, reduces the Aβ42 level with IC50s of 0.017 μM and 0.014 μM in mouse and human, respectively.</p>

<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) &amp; 15.80 nM (JAK3); promising for lymphoid diseases &amp; leukemia research.</p>

<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>

<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>

<p>GSK3-IN-2 is a potent GSK3 inhibitor for the treatment of diabetes and neurodegenerative diseases.</p>

<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>

<p>Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively.</p>

<p>VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.</p>

<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>

<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>

<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>

<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>

<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>

<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>

<p>Yhhu-3792 activates Notch, boosts Hes3/Hes5, enhances NSC renewal, expands NSC pool, and may improve memory.</p>

<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>

<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>

<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>

<p>5-{8-[(3,4'-Difluoro[1,1'-biphenyl]-4-yl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl}-N-methylpyridine-2-carboxamide (1o) exhibited high in vitro potency and</p>

<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>

<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>

<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>

<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) &amp; 19.40 nM (JAK2).</p>

<p>BRD0209 is a highly selective and potent GSK3 inhibitor.</p>

<p>JA310 is a highly selective inhibitor of the MST3 kinase, demonstrating significant cellular potency with an EC50 value of 106 nM [1].</p>

<p>RR-11a is a synthetic enzyme Legumain inhibitor.</p>

<p>BPN-15606, an oral γ-secretase modulator, reduces Aβ42/Aβ40 with IC50 of 7/17 nM; promising PK/PD, lowers Aβ in rodent CNS.</p>

<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>

<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 &amp; JAK3 inhibitor with IC50s of 23.85 nM (JAK2) &amp; 18.9 nM (JAK3).</p>

<p>Aβ42-IN-1 free base (compound 1v), an orally active γ-secretase modulator with high brain exposure, effectively lowers Aβ42 levels, exhibiting an IC 50 of 0.091</p>

<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>

<p>ELN318463 racemate (ELN 318463 racemate) is the racemate of ELN318463 which is an amyloid precursor protein (APP) selective γ-secretase inhibitor.</p>

<p>TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase(IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII,</p>

<p>CIA-1 inhibits the nuclear receptor COUP-TFII, with IC50s ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.CIA-1 inhibits the growth of a variety of</p>

<p>RR-11a (aza-peptide) inhibits asparaginyl endopeptidase: IC50 - 4.5 nM (T. Vaginalis, I. ricinus), 31 nM (S. mansoni).</p>

<p>Wnt pathway activator 2 is a potent Wnt activator with an IC50 of 13 nM.</p>

<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>

JI051 has anti-tumor effects and can interact with PHB2 to inhibit the proliferation of HEK293 cells and pancreatic cancer cells.